文献速递中医内科中药与中成药合理使用

稳心颗粒治疗室性早搏的系统评价

Efficacy and safety of Chinese herbal medicine Wenxin Keli for ventricular premature be ats: A systematic review.
PubMed 文献 · Complement Ther Med · 2016-10-13

该系统评价纳入10项随机对照试验,评估稳心颗粒单用或联用西药治疗室性早搏的疗效与安全性。结果显示稳心颗粒可能优于安慰剂,联用胺碘酮可能优于单用胺碘酮,与美托洛尔、普罗帕酮或美西律可能相当。安全性方面总不良反应发生率与西药无统计学差异,但可能减少致心律失常反应。方法学质量普遍较低。

要点

  • 稳心颗粒可能优于安慰剂改善室性早搏次数及相关症状。
  • 稳心颗粒联用胺碘酮可能优于单用胺碘酮。
  • 稳心颗粒与美托洛尔、普罗帕酮或美西律疗效可能相当。

核心结论

  • 稳心颗粒可能是治疗室性早搏有前景的替代和补充药物。

研究设计与样本

  • 系统评价纳入10项随机对照试验,随机性经联系作者验证。
  • 检索8个核心电子数据库和3个临床试验注册库,中英文文献。
  • 采用Cochrane偏倚风险工具评估纳入试验。

主要发现

  • 稳心颗粒对比安慰剂:室性早搏次数变化RR 1.61(95%CI 1.48-1.76,P<0.00001,I2=0%)。
  • 稳心颗粒对比安慰剂:室性早搏相关症状RR 2.10(95%CI 1.91-2.30,P<0.00001,I2=0%)。
  • 稳心颗粒联用胺碘酮对比单用胺碘酮:室性早搏次数变化RR 1.23(95%CI 1.10-1.39,P=0.0005,I2=0%)。
  • 稳心颗粒联用胺碘酮对比单用胺碘酮:室性早搏相关症状RR 1.51(95%CI 1.30-1.76,P<0.00001,I2=0%)。
  • 稳心颗粒对比美托洛尔、普罗帕酮或美西律的室性早搏次数变化及症状RR均无统计学差异。

关键数值与推荐

  • 室性早搏次数<360次/小时的患者从稳心颗粒治疗中获益最大(RR 1.10,95%CI 1.02-1.20,P=0.02,I2=44%)。
  • 冠心病患者从稳心颗粒治疗中获益最大(RR 1.71,95%CI 1.18-2.49,P=0.005,I2=54%)。
  • 总不良反应发生率稳心颗粒与西药无统计学差异(RR 0.59,95%CI 0.35-1.01,P=0.05,I2=0%)。
  • 稳心颗粒可能降低致心律失常反应风险(P=0.007)。

临床怎么用

  • 可考虑将稳心颗粒作为室性早搏的替代或补充治疗,尤其适用于室性早搏次数<360次/小时或冠心病患者。
  • 稳心颗粒可与胺碘酮联用以增强疗效。
  • 稳心颗粒与美托洛尔、普罗帕酮或美西律疗效相当,可作为选择之一。

局限性

  • 纳入试验方法学质量普遍较低。
  • 样本量小、随机化方法不充分、入选标准定义不清。
  • 随访时间短、缺乏硬终点、发表偏倚风险高(P=0.013)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the efficacy and safety of the Chinese herbal extract Wenxin Keli, alone or in combination with Western medicine, for ventricular premature beats. METHODS: This systematic review was registered at PROSPERO (registration number CRD42013003200). A systematic literature search of 8 core electronic databases and 3 clinical trial registries in Chinese and English, yielded 10 trials whose randomness verified by contacting the authors. The included trials were assessed by the Cochrane risk of bias tool. RESULTS: Wenxin Keli might be more efficacious than placebo (Change of VPBs numbers, RR, 1.61, 95%CI, 1.48-1.76, P<0.00001, I2=0%;VPBs- related symptom, RR, 2.10, 95%CI, 1.91-2.30, P<0.00001, I2=0%), and the dual therapy of Wenxin Keli plus amiodarone might also be more effective than the monotherapy of amiodarone (Change of VPBs numbers, RR, 1.23, 95%CI, 1.10-1.39, P=0.0005, I2=0%; VPBs- related symptom, RR, 1.51., 95%CI, 1.30-1.76, P<0.00001, I2=0%), whereas Wenxin Keli might be comparable to metoprolol, propafenone or mexiletine (Change of VPBs numbers: metoprolol, RR, 1.01, 95%CI, 0.91-1.11, P=0.88, I2=0%; propafenone, RR, 1.05, 95%CI, 0.93-1.19, P=0.44, I2=0%; mexiletine, RR, 1.06, 95%CI, 0.96-1.17, P=0.28. VPBs- related symptom: metoprolol, RR, 0.95, 95%CI, 0.87-1.04, P=0.27, I2=0%, propafenone. RR, 1.10, 95%CI, 0.93-1.30, P=0.29, I2=29%, mexiletine,RR, 0.94, 95%CI, 0.78-1.12, P=0.47). Participants with ventricular premature beats' numbers<360 beats/h or with coronary heart disease benefited the most of the Wenxin Keli therapy (Change of VPBs numbers:RR, 1.10, 95%CI, 1.02-1.20, P=0.02, I2=44%; RR, 1.71, 95%CI, 1.18-2.49, P=0.005, I2=54%, respectively). The safety analysis revealed that Wenxin Keli did not statistically significant differed from the Western medicine in respect of the incidence of total adverse drug reactions (RR, 0.59, 95%CI, 0.35-1.01, P=0.05, I2=0%), but Wenxin Keli might be associated with a reduced risk of proarrhythmic reactions (P=0.007). The quality of the methodology of included trials was generally low. Several limitations existed that affected the validity of the findings, including the small sample size, insufficient randomization methods, poorly defined eligibility criteria, short duration of follow-up, absence of hard endpoints, and high risk of publication bias(P=0.013). CONCLUSIONS: Wenxin Keli might be a promising alternative and complementary medicine for ventricular premature beats.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. He M, Lv Z, Yang ZW, et al. Efficacy and safety of Chinese herbal medicine Wenxin Keli for ventricular premature be ats: A systematic review. Complement Ther Med. 2016. PMID: 27912945. doi:10.1016/j.ctim.2016.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。